Ademi & Fruchter LLP Investigates Claims of Securities Fraud against DexCom, Inc.

Core Viewpoint - Ademi & Fruchter LLP is investigating potential securities fraud claims against DexCom, Inc. due to inaccurate statements regarding its business operations and the quality of its products [1][2]. Group 1: Investigation Details - The investigation centers on DexCom's claims about its G7 blood glucose monitor, asserting it was of high quality and manufactured with FDA-approved materials [2]. - Reports indicate that DexCom altered the sensor membrane coating material from a third-party supplier to an in-house formulation without notifying the FDA or investors, which deviated from the FDA-approved formulation [2]. - The investigation period spans from January 8, 2024, to September 17, 2025 [2].